ArticlePediatric research2026
PFAS exposure in 12-year-old children and its association with metabolic markers.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPer- and polyfluoroalkyl substances (PFAS) are long-lasting industrial chemicals with widespread exposure, but their effects on adolescent cardiometabolic health remain underexplored. This cross-sectional study evaluated associations between PFAS concentrations and metabolic biomarkers at age 12.
methodsThe study included 451 participants from the French PELAGIE mother-child cohort. At age 12, serum levels of six PFAS and metabolic biomarkers (leptin, adiponectin, fructosamine, total cholesterol, LDL, HDL, triglycerides) were measured. Cross-sectional associations were assessed using multivariable linear regression models and Quantile G-computation mixture models, adjusted for potential confounders and stratified by sex and pubertal stage.
resultsIn the overall population, perfluoroundecanoic acid (PFUdA) was associated with higher total cholesterol and LDL cholesterol levels. In pre-menarcheal girls, perfluorohexane sulfonate (PFHxS) was associated with higher total cholesterol and LDL cholesterol levels, and PFAS mixture analyses also showed positive associations with these lipid markers. In boys, perfluorononanoic acid (PFNA) and perfluorodecanoic acid (PFDA) were associated with higher triglyceride levels in peripubertal boys, whereas perfluorooctane sulfonate (PFOS) was associated with lower triglyceride levels in postpubertal boys.
conclusionFindings indicate potential associations between PFAS exposure and metabolic biomarkers at age 12, with variations by sex and pubertal status, emphasizing the need for longitudinal investigations. IMPACT: PFAS were detected in all serum samples, showing widespread exposure among the adolescents. Exposure to PFAS was associated with blood lipid markers at age 12, with differences in associations observed across sex- and pubertal stage-specific groups. This study is one of the few to consider the stage of pubertal development in the associations between PFAS and metabolic health markers. The findings suggest that pubertal development should be considered when evaluating the health effects of PFAS exposure during adolescence.
Identifiers
42881263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.